Vyant Bio, Inc. Common Stock

VYNT

Capitalización de mercado USD 1.63 M

Acerca de: Vyant Bio Inc incorporates biology and data science to improve drug discovery for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. The company's platform is designed to: 1) elucidate disease pathophysiology; 2) formulate key therapeutic hypotheses; 3) identify and validate drug targets, cellular assays, and biomarkers to guide candidate molecule selection; and 4) guide clinical trial patient selection and trial design. The majority of revenue is earned in the United States.

Empleados: 8